PARP1 and prostate carcinoma: PARP inhibitors have recently been approved as monotherapy for patients with advanced prostate cancer with defects in homologous recombination who have failed a second-generation hormonal agent (and a taxane chemotherapy in the case of rucaparib)7,28.